GO
Loading...

Express Scripts Holding Co

More

  • Early Glance: Drug Benefits companies Thursday, 19 Feb 2015 | 10:51 AM ET

    NEW YORK— Shares of some top drug benefits companies are mixed at 10 a.m.:. CVS Health Corp. fell$. 08 or. 1 percent, to $104.02. Express Scripts Holding Co. rose$. 21 or. 2 percent, to $85.38.

  • Final Glance: Drug Benefits companies Wednesday, 18 Feb 2015 | 6:30 PM ET

    NEW YORK— Shares of some top drug benefits companies were mixed at the close of trading:. CVS Health Corp. rose$. 55 or. 5 percent, to $104.10. Express Scripts Holding Co. fell$. 02 or percent, to $85.17.

  • Midday Glance: Drug Benefits companies Wednesday, 18 Feb 2015 | 1:18 PM ET

    NEW YORK— Shares of some top drug benefits companies are down at 1 p.m.:. CVS Health Corp. fell$. 02 or percent, to $103.53. Express Scripts Holding Co. fell$. 24 or. 3 percent, to $84.95.

  • Early Glance: Drug Benefits companies Wednesday, 18 Feb 2015 | 10:54 AM ET

    NEW YORK— Shares of some top drug benefits companies are down at 10 a.m.:. CVS Health Corp. fell$. 05 or percent, to $103.50. Express Scripts Holding Co. fell$. 32 or. 4 percent, to $84.88.

  • Buffett's Berkshire builds Deere stake, dumps Exxon Wednesday, 18 Feb 2015 | 7:19 AM ET
    A John Deere 8600 tractor is displayed on opening day of the World Ag Expo on February 10, 2015 in Tulare, Calif.

    Warren Buffett's Berkshire Hathaway disclosed a 5 percent stake in Deere & Co. and said it shed a $3.74 billion investment in Exxon Mobil.

  • NEW YORK, Feb 17- Warren Buffett's Berkshire Hathaway Inc on Tuesday disclosed a 5 percent stake in agricultural equipment maker Deere& Co and said it shed a $3.74 billion investment in oil company Exxon Mobil Corp as oil prices plunged. The changes were among several that Berkshire made in its common stock investments in the fourth quarter, according to a U.S....

  • Final Glance: Drug Benefits companies Tuesday, 17 Feb 2015 | 6:09 PM ET

    NEW YORK— Shares of some top drug benefits companies were up at the close of trading:. CVS Health Corp. rose$. 92 or. 9 percent, to $103.55. Express Scripts Holding Co. rose$. 29 or. 3 percent, to $85.19.

  • Midday Glance: Drug Benefits companies Tuesday, 17 Feb 2015 | 1:32 PM ET

    NEW YORK— Shares of some top drug benefits companies are mixed at 1 p.m.:. CVS Health Corp. fell$. 03 or percent, to $102.60. Express Scripts Holding Co. rose$. 18 or. 2 percent, to $85.08.

  • Early Glance: Drug Benefits companies Tuesday, 17 Feb 2015 | 11:00 AM ET

    NEW YORK— Shares of some top drug benefits companies are mixed at 10 a.m.:. CVS Health Corp. fell$. 47 or. 5 percent, to $102.16. Express Scripts Holding Co. rose$. 09 or. 1 percent, to $84.99.

  • Final Glance: Drug Benefits companies Friday, 13 Feb 2015 | 6:13 PM ET

    NEW YORK— Shares of some top drug benefits companies were mixed at the close of trading:. CVS Health fell$. 37 or. 4 percent, to $102.63. Express Scripts Holding rose$. 40 or. 5 percent, to $84.90.

  • Midday Glance: Drug Benefits companies Friday, 13 Feb 2015 | 1:23 PM ET

    NEW YORK— Shares of some top drug benefits companies are down at 1 p.m.:. CVS Health Corp. fell$. 43 or. 4 percent, to $102.57. Express Scripts Holding Co. unchanged at $84.50.

  • Early Glance: Drug Benefits companies Friday, 13 Feb 2015 | 11:05 AM ET

    NEW YORK— Shares of some top drug benefits companies are down at 10 a.m.:. CVS Health Corp. fell$. 11 or. 1 percent, to $102.89. Express Scripts Holding Co. fell$. 22 or. 3 percent, to $84.28.

  • Drug price wars 'drive value': Medical exec Friday, 6 Feb 2015 | 5:21 PM ET
    Hepatitis C sufferers and supporters hold placards during a demonstration outside of US laboratory Gilead Sciences office in Madrid on February 5, 2015.

    Price cuts, which may hurt pharmaceutical margins, are fundamentally better for consumers, said Dr. Steve Miller of Express Scripts.

  • Pricing wars heat up over hepatitis C drugs Wednesday, 4 Feb 2015 | 12:13 PM ET
    A researcher works on a hepatitis C virus drug at Gilead Sciences lab in Foster City, Calif.

    Discounts on Gilead's hepatitis C drugs this year will be 46 percent, way more than investors and analysts expected.

  • Jan 30- AbbVie Inc's chief executive said on Friday the company's new oral hepatitis C treatment Viekira Pak has the potential to capture a "meaningful share" of the U.S. market, where it is competing against Gilead Sciences. AbbVie CEO Richard Gonzalez told investors the company expects an annualized sales run rate of more than $3 billion by the end of 2015, which...

  • Drugmaker AbbVie beats as Humira sales rise Friday, 30 Jan 2015 | 11:34 AM ET
    AbbVie facility in Ireland

    U.S. drugmaker AbbVie's revenue beat analysts' estimates for the fourth straight quarter as sales of arthritis drug Humira jumped nearly 11 percent.

  • Jan 30- U.S. drugmaker AbbVie Inc's revenue beat analysts' estimates for the fourth straight quarter as sales of arthritis drug Humira jumped nearly 11 percent. Excluding the charge and other special items, AbbVie earned 89 cents per share. Sales of Humira, which AbbVie inherited from Abbott Laboratories in 2013, rose to $3.36 billion in the fourth quarter ended...

  • Trend trader: Playing a euro fall to parity Friday, 30 Jan 2015 | 7:00 AM ET

    From a U.S. trading perspective, here are the ways to play the strengthening dollar of 2015.

  • Jan 26- Pharmacy benefits manager EnvisionRx said on Monday it reached an agreement to provide its customers with Gilead Sciences Inc's hepatitis C drugs on an exclusive basis, the latest Gilead victory in a market share battle with AbbVie over their new treatments for the liver destroying virus. EnvisionRx said Gilead's Sovaldi and its newer two-drug...

  • Benefits firms shouldn't play drug favorites: CEO Tuesday, 20 Jan 2015 | 10:00 AM ET

    Regeneron Pharmaceuticals CEO Dr. Leonard Schleifer told CNBC on Tuesday that benefits companies should not try to practice medicine.